UNLABELLED: Activin-A is expressed in bone and seems to regulate osteoclastogenesis. In this study, serum activin-A was increased in postmenopausal women with low bone mass and was positively correlated to age and negatively to lumbar spinal bone mineral density (BMD). Serum activin-A levels did not change 3 months after zoledronic acid infusion. INTRODUCTION: The aims of the study were to evaluate prospectively the circulating activin-A levels in postmenopausal women with low bone mass and explore possible correlations with clinical and laboratory data, as well as the 3-month effect of zoledronic acid infusion. METHODS:Postmenopausal women with low bone mass assigned to receive zoledronic acid infusion (Patients, n = 47) and age-matched, postmenopausal women with normal bone mass (Controls, n = 27) were recruited on an outpatient basis. Main outcome measurement was serum activin-A levels. RESULTS:Serum activin-A was higher in patients at baseline compared to controls (p < 0.001) and activin-A in the serum of patients and controls was positively correlated with age (Spearman's coefficient of correlation [rs] = 0.325; p = 0.005) and negatively with lumbar spinal (LS) BMD (rs = -0.425; p < 0.001). In multiple linear regression analysis, only age (B = 8.93; 95 % CI = 4.39-13.46; p < 0.001) was associated with serum activin-A levels at baseline, independent from group (patients or controls), previous anti-osteoporotic treatment, LS BMD and follicle-stimulating hormone. Circulating activin-A levels were not affected 3 months after zoledronic acid infusion. CONCLUSIONS:Serum activin-A is increased in postmenopausal women with low bone mass compared with postmenopausal women with normal bone mass and is positively correlated to age and negatively to LS BMD.
RCT Entities:
UNLABELLED: Activin-A is expressed in bone and seems to regulate osteoclastogenesis. In this study, serum activin-A was increased in postmenopausal women with low bone mass and was positively correlated to age and negatively to lumbar spinal bone mineral density (BMD). Serum activin-A levels did not change 3 months after zoledronic acid infusion. INTRODUCTION: The aims of the study were to evaluate prospectively the circulating activin-A levels in postmenopausal women with low bone mass and explore possible correlations with clinical and laboratory data, as well as the 3-month effect of zoledronic acid infusion. METHODS: Postmenopausal women with low bone mass assigned to receive zoledronic acid infusion (Patients, n = 47) and age-matched, postmenopausal women with normal bone mass (Controls, n = 27) were recruited on an outpatient basis. Main outcome measurement was serum activin-A levels. RESULTS: Serum activin-A was higher in patients at baseline compared to controls (p < 0.001) and activin-A in the serum of patients and controls was positively correlated with age (Spearman's coefficient of correlation [rs] = 0.325; p = 0.005) and negatively with lumbar spinal (LS) BMD (rs = -0.425; p < 0.001). In multiple linear regression analysis, only age (B = 8.93; 95 % CI = 4.39-13.46; p < 0.001) was associated with serum activin-A levels at baseline, independent from group (patients or controls), previous anti-osteoporotic treatment, LS BMD and follicle-stimulating hormone. Circulating activin-A levels were not affected 3 months after zoledronic acid infusion. CONCLUSIONS: Serum activin-A is increased in postmenopausal women with low bone mass compared with postmenopausal women with normal bone mass and is positively correlated to age and negatively to LS BMD.
Authors: Li Sun; Yuanzhen Peng; Allison C Sharrow; Jameel Iqbal; Zhiyuan Zhang; Dionysios J Papachristou; Samir Zaidi; Ling-Ling Zhu; Beatrice B Yaroslavskiy; Hang Zhou; Alberta Zallone; M Ram Sairam; T Rajendra Kumar; Wei Bo; Jonathan Braun; Luis Cardoso-Landa; Mitchell B Schaffler; Baljit S Moonga; Harry C Blair; Mone Zaidi Journal: Cell Date: 2006-04-21 Impact factor: 41.582
Authors: Marco Eijken; Sigrid Swagemakers; Marijke Koedam; Cobie Steenbergen; Pieter Derkx; André G Uitterlinden; Peter J van der Spek; Jenny A Visser; Frank H de Jong; Huibert A P Pols; Johannes P T M van Leeuwen Journal: FASEB J Date: 2007-04-20 Impact factor: 5.191
Authors: Matthew T Drake; Louise K McCready; Kelley A Hoey; Elizabeth J Atkinson; Sundeep Khosla Journal: J Clin Endocrinol Metab Date: 2010-07-07 Impact factor: 5.958
Authors: E Terpos; E Kastritis; D Christoulas; M Gkotzamanidou; E Eleutherakis-Papaiakovou; N Kanellias; A Papatheodorou; M A Dimopoulos Journal: Ann Oncol Date: 2012-04-06 Impact factor: 32.976
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Anders Nordholm; Søren Egstrand; Eva Gravesen; Maria L Mace; Marya Morevati; Klaus Olgaard; Ewa Lewin Journal: Pflugers Arch Date: 2019-06-24 Impact factor: 3.657
Authors: Fabio Vescini; Iacopo Chiodini; Alberto Falchetti; Andrea Palermo; Antonio Stefano Salcuni; Stefania Bonadonna; Vincenzo De Geronimo; Roberto Cesareo; Luca Giovanelli; Martina Brigo; Francesco Bertoldo; Alfredo Scillitani; Luigi Gennari Journal: Int J Mol Sci Date: 2021-12-20 Impact factor: 5.923